Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. B-cell receptor (BCR) pathway is essential for malignant B-cell growth, survival, and proliferation. Various immune cells, including T-cells and macrophages in the tumor microenvironment (TME) contribute to tumor cell survival and pat...

Full description

Saved in:

Bibliographic Details
Main Authors:	Dipenkumar Modi, Bindu Potugari, Joseph Uberti
Format:	article
Language:	EN
Published:	MDPI AG 2021
Subjects:	diffuse large B-cell lymphoma (DLBCL) autologous stem cell transplant (autoSCT) allogeneic stem cell transplant (alloSCT) CAR T-cell therapy bispecific T-cell engager antibody immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Online Access:	https://doaj.org/article/a418c832eb2f477cb6afc86424d80a53
Tags:	Add Tag No Tags, Be the first to tag this record!

id	oai:doaj.org-article:a418c832eb2f477cb6afc86424d80a53
record_format	dspace
spelling	oai:doaj.org-article:a418c832eb2f477cb6afc86424d80a532021-11-25T17:04:28ZImmunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions10.3390/cancers132258272072-6694https://doaj.org/article/a418c832eb2f477cb6afc86424d80a532021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5827https://doaj.org/toc/2072-6694Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. B-cell receptor (BCR) pathway is essential for malignant B-cell growth, survival, and proliferation. Various immune cells, including T-cells and macrophages in the tumor microenvironment (TME) contribute to tumor cell survival and pathogenesis of chemo-resistance. The presence of many targets on the malignant B-cells and in the TME has led to emergence of novel therapeutic agents. Stem cell transplant is the oldest treatment modality leveraging immune system in DLBCL. Subsequently, CD20 targeting monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy changed the treatment landscape of DLBCL. Recently, multiple novel immunotherapeutic agents have been added in the armamentarium for the management of DLBCL, and many are under development. In this review article, we will review latest updates of immunotherapeutic agents in the management of DLBCL.Dipenkumar ModiBindu PotugariJoseph UbertiMDPI AGarticlediffuse large B-cell lymphoma (DLBCL)autologous stem cell transplant (autoSCT)allogeneic stem cell transplant (alloSCT)CAR T-cell therapybispecific T-cell engager antibodyimmunotherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5827, p 5827 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	diffuse large B-cell lymphoma (DLBCL) autologous stem cell transplant (autoSCT) allogeneic stem cell transplant (alloSCT) CAR T-cell therapy bispecific T-cell engager antibody immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	diffuse large B-cell lymphoma (DLBCL) autologous stem cell transplant (autoSCT) allogeneic stem cell transplant (alloSCT) CAR T-cell therapy bispecific T-cell engager antibody immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Dipenkumar Modi Bindu Potugari Joseph Uberti Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
description	Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. B-cell receptor (BCR) pathway is essential for malignant B-cell growth, survival, and proliferation. Various immune cells, including T-cells and macrophages in the tumor microenvironment (TME) contribute to tumor cell survival and pathogenesis of chemo-resistance. The presence of many targets on the malignant B-cells and in the TME has led to emergence of novel therapeutic agents. Stem cell transplant is the oldest treatment modality leveraging immune system in DLBCL. Subsequently, CD20 targeting monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy changed the treatment landscape of DLBCL. Recently, multiple novel immunotherapeutic agents have been added in the armamentarium for the management of DLBCL, and many are under development. In this review article, we will review latest updates of immunotherapeutic agents in the management of DLBCL.
format	article
author	Dipenkumar Modi Bindu Potugari Joseph Uberti
author_facet	Dipenkumar Modi Bindu Potugari Joseph Uberti
author_sort	Dipenkumar Modi
title	Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
title_short	Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
title_full	Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
title_fullStr	Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
title_full_unstemmed	Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
title_sort	immunotherapy for diffuse large b-cell lymphoma: current landscape and future directions
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a418c832eb2f477cb6afc86424d80a53
work_keys_str_mv	AT dipenkumarmodi immunotherapyfordiffuselargebcelllymphomacurrentlandscapeandfuturedirections AT bindupotugari immunotherapyfordiffuselargebcelllymphomacurrentlandscapeandfuturedirections AT josephuberti immunotherapyfordiffuselargebcelllymphomacurrentlandscapeandfuturedirections
_version_	1718412731002912768

Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions

Similar Items